Kevin McCulloch, President and Chief Operating Officer of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS), filed a statement of changes in beneficial ownership on August 21, 2026, disclosing a share disposition on August 1, 2026 related to the net settlement of vested restricted stock units.
Key Highlights
- Reporting person: Kevin McCulloch, President and Chief Operating Officer of Xeris Biopharma Holdings, Inc.
- Transaction date: August 1, 2026, involving Common Stock with transaction code "F"
- Shares disposed: 21,918 shares withheld by the issuer at $8.08 per share to satisfy tax withholding obligations upon RSU vesting
- Resulting direct ownership: 1,654,208 shares of Common Stock held directly following the reported transaction
- Indirect holdings: 25,000 shares held indirectly by spouse, with McCulloch disclaiming beneficial ownership except to the extent of his pecuniary interest
RSU Settlement and Share Withholding at Xeris Biopharma
According to the filing, the 21,918 shares reported as disposed of represent shares withheld by Xeris Biopharma Holdings, Inc. to satisfy income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units that vested as of August 1, 2026. The transaction was coded "F," indicating shares withheld for taxes rather than an open-market sale, and the price recorded was $8.08 per share.
Xeris Biopharma Holdings, Inc., a biopharmaceutical company headquartered at 1375 West Fulton Street, Suite 1300, Chicago, Illinois 60607, has its Common Stock listed on NASDAQ under the symbol XERS. Following the disposition, McCulloch reported direct beneficial ownership of 1,654,208 shares of Common Stock. An additional 25,000 shares are reported as indirectly owned through his spouse, though the filing states he "disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein."
The filing was signed by Beth Hecht as Attorney-in-Fact on August 21, 2026, and was filed by one reporting person. No derivative securities transactions were reported in Table II of the filing.
What Was Disclosed
The filing disclosed a single tax-withholding disposition of 21,918 Common Stock shares by Xeris Biopharma's President and COO upon RSU vesting, leaving him with 1,654,208 shares held directly and 25,000 shares held indirectly by his spouse.



Please wait processing your request...